Abstract
Natural killer (NK)/T-cell lymphoma–associated hemophagocytic lymphohistiocytosis (NK/T-LAHLH) is a rare and life-threatening disorder. Its clinical characteristics and appropriate treatment options are unclear. This study aimed to investigate the clinical characteristics and treatment options for this disease. We retrospectively analyzed the clinical data of 84 patients with NK/T-cell lymphoma and compared the characteristics, treatment, and survival between patients with and without HLH. Patients in the NK/T-LAHLH group were more likely to be younger age and have hepatosplenomegaly, B symptoms, neutropenia, anemia, thrombocytopenia, elevated lactate dehydrogenase levels, reduced serum albumin levels, bone marrow involvement, Ann Arbor stage III/IV, and International Prognostic Index score ≥ 3. After multivariate analysis, it was found that elevated lactate dehydrogenase and Ann Arbor stage III/IV were risk factors for HLH in patients with NK/T-cell lymphoma. After 2 weeks of therapy, 78.6% (11/14) patients who received the L-DEP/DEP regimen achieved an overall response rate of HLH, which was higher than that in 42.9% (9/21) patients who received the VP-16 + dexamethasone-based regimen. NK/T-LAHLH patients had poorer survival than non-HLH-NK/TCL patients. For NK/T-LAHLH, the L-DEP/DEP regimen may have a better response rate than the VP-16 + dexamethasone-based regimens.
Similar content being viewed by others
References
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131
Skinner J, Yankey B, Shelton BK (2019) Hemophagocytic lymphohistiocytosis. AACN Adv. Crit Care 30(2):151–164
Rivière S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, Fardet L (2014) Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med 127(11):1118–1125
Lehmberg K, Nichols KE, Henter JI, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, La Rosée P, Weitzman S, Study Group on HemophagocyticLymphohistiocytosis Subtypes of the Histiocyte Society (2015) Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100(8):997–1004
Fugl A, Andersen CL (2019) Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract 20(1):62
Goudarzipour K, Kajiyazdi M, Mahdaviyani A (2013) Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis. Int J Hematol Oncol Stem Cell Res 7(1):42–45
Takahashi N, Miura I, Chubachi A, Miura AB, Nakamura S (2001) A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol 74(3):303–308
Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, Yamamoto K, Horiuchi H, Takada K, Ohshima K, Nakamura S, Kinukawa N, Oshimi K, Kawa K (2007) Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86(1):58–65
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–86
Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, Lee ND, Khan SP, Lawrence J, Mo JQ, Bleesing JJ, Filipovich AH, Jordan MB (2013) Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 60(1):101–9
Jia J, Song Y, Lin N, Liu W, Ping L, Zheng W, Wang X, Xie Y, Tu M, Zhang C, Ying Z, Deng L, Ding N, Zhu J (2016) Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome. Ann Hematol 95(12):2023–2031
Li N, Zhang L, Liu J, Zhang J, Weng HW, Zhuo HY, Zou LQ (2017) A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer/T cell lymphoma. Cancer Biol Ther 18(4):252–256. https://doi.org/10.1080/15384047.2017.1295176
Liu YZ, Bi LQ, Chang GL, Guo Y, Sun S (2019) Clinical characteristics of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Cancer Manag Res 23(11):997–1002
Han L, Zhang M, Li L, Zhang L, Wu J, Li X, Wang X, Young KH, Fu X, Ma W, Sun Z, Zhang X, Chang Y, Qiao Z (2014) Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: a case report. Oncol Lett 8(2):886–890
Wei L, Yang L, Cong J, Ye J, Li X, Yao N, Yang J, Ding J, Wang J (2020) Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. J Cancer Res Clin Oncol 6:1–7
Han L, Li L, Wu J, Li X, Zhang L, Wang X, Fu X, Ma W, Sun Z, Zhang X, Chang Y, Guo S, Zhang M (2014) Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. Leuk Lymphoma 55(9):2048–2055
Li DH, Zhang XY, Du C, Zhang WH, Chang J, Ma YJ, Li ZC, Hao SG, Ding H, Tao R (2017) Successful treatment of extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis with MEDA chemotherapy. Leuk Lymphoma 58(5):1238–1241
Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z (2016) PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol 9(1):84
Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K (2005) Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130(6):860–868
Yu JT, Wang CY, Yang Y, Wang RC, Chang KH, Hwang WL, Teng CL (2013) Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol 92(11):1529–1536
Machaczka M, Nahi H, Karbach H, Klimkowska M, Hägglund H (2012) Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. Med Oncol 29(2):1231–1236
Funding
This work was supported by the National Natural Science Foundation of China (No. 81871633).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
The work was approved by the Institutional Review Board of Friendship Hospital. The study has been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.
Informed consent
Informed consent was obtained from all participants included in this study.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Meng, G., Wang, J., Cui, T. et al. Clinical characteristics and treatment of NK/T-cell lymphoma–associated HLH. Ann Hematol 101, 2289–2296 (2022). https://doi.org/10.1007/s00277-022-04953-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-022-04953-1